PMGC Holdings (ELAB) Net Income towards Common Stockholders (2022 - 2026)
PMGC Holdings (ELAB) posted Net Income towards Common Stockholders of $19501.0 for Q1 2026, down 10.29% sequentially from $21738.0 in Q4 2025, and up 170.54% YoY from $7208.1 in Q1 2025.
PMGC Holdings (ELAB) Net Income towards Common Stockholders (2022 - 2026) Analysis & Trends
PMGC Holdings has reported Net Income towards Common Stockholders for 5 years, with the latest figure at $19501.0 in Q1 2026.
- Quarterly Net Income towards Common Stockholders rose 170.54% year-over-year to $19501.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $80072.0 (up 105.71% YoY) and the FY2025 annual result came in at $32927.0, up 101.48% from the prior year.
- Net Income towards Common Stockholders declined to $19501.0 in Q1 2026 per ELAB's latest filing, from $21738.0 in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at $21738.0 in Q4 2025 and troughed at -$3.1 billion in Q4 2023.
- A 5-year average of -$335.3 million and a median of -$843918.0 in 2023 frame the typical range for Net Income towards Common Stockholders.
- The sharpest annual moves came in 2023 and 2026: Net Income towards Common Stockholders plunged 173.98% in 2023, then soared 170.54% in 2026.
- Over 5 years, Net Income towards Common Stockholders stood at -$1.1 billion in 2022, then slumped by 173.98% to -$3.1 billion in 2023, then soared by 99.99% to -$216910.0 in 2024, then soared by 110.02% to $21738.0 in 2025, then retreated by 10.29% to $19501.0 in 2026.
- According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered $19501.0, $21738.0, and $21698.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | PMGC Holdings | 31.22 Mn | 12.43 Mn | 385,691.00 | -4.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 19,501.00 |
| Dec 31, 2025 | 21,738.00 |
| Sep 30, 2025 | 21,698.00 |
| Jun 30, 2025 | 17,135.00 |
| Mar 31, 2025 | -27,644.00 |
| Dec 31, 2024 | -216,910.00 |
| Sep 30, 2024 | -299,404.00 |
| Jun 30, 2024 | -859,580.00 |
| Mar 31, 2024 | -1.87 Mn |
| Dec 31, 2023 | -3.14 Bn |
| Sep 30, 2023 | -270.32 Mn |
| Jun 30, 2023 | -1.06 Mn |
| Mar 31, 2023 | -843,918.00 |
| Dec 31, 2022 | -1.15 Bn |
| Sep 30, 2022 | -469.32 Mn |